-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UaLUI9PtorQAouer5heJXURPaNbF14ASePcNkU3pLUQQg5c8cg7nUuZ8zXkhYwr5
 uUuio0w6zi2chQ8Ma/DOpQ==

<SEC-DOCUMENT>0001193125-04-218094.txt : 20041222
<SEC-HEADER>0001193125-04-218094.hdr.sgml : 20041222
<ACCEPTANCE-DATETIME>20041222110238
ACCESSION NUMBER:		0001193125-04-218094
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041222
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041222
DATE AS OF CHANGE:		20041222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		041219447

	BUSINESS ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): December 22, 2004
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>OraSure Technologies, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact
Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>001-16537</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-4370966</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>220 East First Street</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Bethlehem, Pennsylvania</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>18015-1360</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: 610-882-1820 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 7.01 &#150; Regulation FD Disclosure </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On December 22, 2004, OraSure Technologies, Inc. (the &#147;Company&#148;) issued a press release (i) announcing that The Centers for
Disease Control and Prevention will purchase approximately $2.3 million of the Company&#146;s OraQuick</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"><I>ADVANCE</I><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> Rapid HIV-1/2
Antibody Tests, and (ii) updating the Company&#146;s financial guidance for 2005. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is incorporated herein by reference. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item 9.01 &#150; Financial Statements and Exhibits </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>(c) Exhibits </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Number</B></FONT></P><HR WIDTH="42"
SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P><HR WIDTH="61" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release dated December 22, 2004, (i) announcing that The Centers for Disease Control and Prevention will purchase approximately $2.3 million of the Company&#146;s OraQuick<FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> <I>ADVANCE</I><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> Rapid HIV-1/2 Antibody Tests, and (ii) updating the Company&#146;s financial guidance
for 2005.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Signatures </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">O<SMALL>RA</SMALL>S<SMALL>URE</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date: December 22, 2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">/s/ Jack E. Jerrett</FONT></P><HR WIDTH="73%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Jack E. Jerrett</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President, General Counsel</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">and Secretary</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><U>Index to Exhibits</U> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT><BR><HR WIDTH="63" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P><HR WIDTH="61" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">99</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release dated December 22, 2004, (i) announcing that The Centers for Disease Control and Prevention will purchase approximately $2.3 million of the Company&#146;s OraQuick<FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> <I>ADVANCE</I><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> Rapid HIV-1/2 Antibody Tests, and (ii) updating the Company&#146;s financial guidance
for 2005.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>

</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>dex99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top">

<IMG SRC="g7926679266.jpg" ALT="LOGO"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Investor Contact</U>: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Ronald H. Spair </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">610-882-1820 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Investorinfo@orasure.com</U> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>www.orasure.com </U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><U>Media Contact: </U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Ron Ticho or Jennifer Moritz </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Zer0 to 5ive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">610-360-0205 or 917-748-4006 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">rticho@orasure.com or jmoritz@0to5.com </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>CDC TO PURCHASE $2.3 MILLION WORTH OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ORAQUICK<FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></B><B><I><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">ADVANCE</FONT></I></B><B><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT> RAPID HIV-1/2 ANTIBODY TESTS
</FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>- </I></B><I>Company Updates Financial
Guidance for 2005 -</I> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>BETHLEHEM, PA</B> &#150; December 22, 2004 &#150;
OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, announced today that The Centers for Disease Control and Prevention (&#147;CDC&#148;) will purchase approximately $2.3 million of the Company&#146;s
OraQuick</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>ADVANCE</I><B><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT></B> Rapid HIV-1/2 Antibody Tests. The CDC purchase is expected to be fulfilled by
September 30, 2005. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This is the first bulk purchase of the
OraQuick</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>ADVANCE</I><B><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT></B> test. Two other bulk purchases of the Company&#146;s OraQuick</FONT><FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> Rapid HIV-1 Antibody test totaling $4 million were previously made by the CDC in June and December of
2003. The CDC is purchasing the OraQuick</FONT><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>ADVANCE</I><B><FONT FACE="Times New Roman"
SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT></B> tests for further distribution to and use by state health departments,
clinics and other entities in the public health sector in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">&#147;We are extremely grateful for the CDC&#146;s continuing support of rapid HIV testing and are very pleased to announce this procurement of our new OraQuick</FONT><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>ADVANCE</I><B><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT></B> test,&#148; said Douglas A. Michels, President and CEO of OraSure Technologies. &#147;We believe our OraQuick</FONT><FONT FACE="Times New Roman"
SIZE="1" COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>ADVANCE</I><B><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT></B> test is the most versatile and comprehensive rapid HIV test available, and OraSure is committed to working with the CDC and other government and
state agencies to implement rapid HIV testing on a large scale across the country.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">&#147;With today&#146;s third bulk purchase of OraSure&#146;s rapid HIV test by the CDC, I am optimistic that expanded distribution of the test will result in increased identification of infected individuals, a
critical step in addressing the significant public health problems that the spread of HIV/AIDS poses for our country,&#148; said Senator Rick Santorum (R-PA), Chairman of the Senate Republican Conference. &#147;OraSure&#146;s rapid HIV test plays an
important role in complementing our public health strategies for research, prevention initiatives and efforts to expand access to quality health care and services for those who need them.&#148; </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The OraQuick</FONT><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><SUP><SUP>&reg;</SUP><SUP></SUP></SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>ADVANCE</I><B><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><SUP>&#153;<FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"></FONT></FONT></B> Rapid HIV-1/2 Antibody Test, manufactured and sold by OraSure Technologies, is the first and only U.S. Food and Drug Administration
(&#147;FDA&#148;) approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid, point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole
blood and plasma specimens. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Updated Financial Guidance for 2005 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">As previously announced, OraSure expects total revenues for 2005 to increase by 25% over 2004 levels, to approximately $67.5 million. In
addition, OraSure expects to achieve full-year profitability for 2005, with net income ranging from $0.06 to $0.08 per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About OraSure Technologies </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices and tests and other diagnostic products using its proprietary technologies,
including immunoassays and other in vitro diagnostic tests and other medical devices. These products are sold in the United States and certain foreign countries to clinical laboratories, hospitals, clinics, community-based organizations and other
public health organizations, distributors, government agencies, physicians&#146; offices, and commercial and industrial entities. For more information on the Company, please visit <U>www.orasure.com.</U> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Important Information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This press release contains certain forward-looking statements, including with respect to revenues, net income and products. Actual results
could be significantly different. Factors that could affect results include the ability to market products; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market
acceptance of oral fluid testing products and up-converting phosphor technology products; ability to fund research and development and other projects and operations; ability to maintain new or existing product distribution channels; reliance on sole
supply sources for critical product components; availability of related products produced by third parties; ability to obtain, and timing of obtaining, necessary regulatory approvals; ability to comply with applicable regulatory requirements;
history of losses and ability to achieve sustained profitability; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; availability of licenses to patents or other technology; ability to
enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally; loss or impairment of sources of capital; ability to meet financial covenants in
agreements with financial institutions; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; changes in relationships with strategic
partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; changes in accounting practices or interpretation of accounting requirements; customer consolidations and inventory practices;
equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; ability to complete consolidation or restructuring activities; ability to identify, complete and realize the full
benefits of potential acquisitions; and general political, business and economic conditions. These and other factors are discussed more fully in the Securities and Exchange Commission (&#147;SEC&#148;) filings of OraSure Technologies, including its
registration statements, its Annual Report on Form 10-K for the year ended December 31, 2003, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Although forward-looking statements help to provide complete information about
future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g7926679266.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g7926679266.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!6`5H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#BFB?<?E/6
MCRG_`+IKISI7)^7O2?V5_LU[/.CBY&<SY3_W31Y3_P!TUT_]D-MW;#C.,U-:
M:;"LX%S&3"_RN1U4>H]QUHYT'LV<EY3_`-TU)<V4]K.8I$P0`0?4$9!'U!KK
M+_PY+I]R89`&!&Z.1?NR*>A%:NH:&+_PQ8:DB9EM0;:?W4'Y3^&<?E4NJM!^
MS9P4>GRRZ?/=@'$#HK#_`'L_X57\I_[IKT?1M%$OA77%V\_NV7_@))JAX?\`
M#8U'68(9%_<JV^7_`'1R?SZ?C2]JM;]`]FSBI[2:WE,4B8<`$CTR,_UIGE/_
M`'377ZC9&\U.YN-O^ME9@`/4\5/?>'ETZVBAE7-W*`\B_P#/)>R_4]3^%5[1
M:7%[-G$^4_\`=-'E/_=-=/\`V4?[IH_LK_9I\Z#D9R_E/_=-?0_A<8\+:6#_
M`,^D?_H(KQ_^RO\`9KV704\O0+!/[MN@_05R8J5TC:E&S9H4445PFX4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`'GQTL9/%*ND%SA5R?3O74_81Z4?8/:NGVA-CFH+-K:0_(&4\/&XX
M8>A%67\/0W49GL,\?>@8_,OT/<5T2PAAMGC$@[$]1^-.2P6-Q);N5([&I=1A
M8Q;&QCO[$Z9=C#Q9,#D<KZBK.B:?Y$%YIERGROR1V(/&1^E;#6Z3,LC)LE7H
MPJ;8NX.0-P&,U#G?0=C%T;2OLEI?6CC[[%?J,?\`UZ@TC31IVE75R5Q)(A4'
MT`_^O718IK1HZ;&4;?2ESL+',Z3HD5E&=2NT!,8S&A]?7_"J/]DW.J7<DQ7+
M.VYW;@+78SVZW`57/R#D@=ZAE@>2/R8E$<7?MFJ51WN%CE)M/M[=3#;#>W1Y
MB.OLOH/>JG]EC^[78?V?"GWLN?0<"F/:;N`H5?115JH*QR7]ECTKN=.3R]-M
MD_NQ*/TJA]A'I6K"NR%%]%`J)RYAI6'T445D,****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!NT>E+@4M
M%`";1Z"C:!TI:*`"BBH[@.UO((_OE3CZU,G9-C6K$6XB:0HK;B.N!G%2UB6=
MXMNNT_*1U!J_9SO<RO)@B/``/J:X,-CHUK)_$^G8VJ47'7H7*0C-+17HF`W:
M/2C:/2G44`-VCTI1TI:*`,/QGK%QH/A2^U*T"^?$@$989`)(&<>V:\_T_7?%
M&CZCX;N[W6VU"WUTC?;R(`(P2!P?^!#IZ5V'Q._Y$#4OHG_H:UP^I?ZGX=?1
M/_0DKKHQ3AJN_P"1C-NYZC)XDT2*>6"35+5989%BD0R#<KDX"X]323^)M"M=
M1&G3ZM:QW9('DM*`V3V]C7">&-&T[5?B9XGEOK5+AK:X#P[QD(VX\X]>*YOQ
MK#H=G;:I:Z5#<7]U]M$MYJ,H4K`Y)_=JV,G)S^5*-&+ERC<VE<[/QEK&M7'C
M33?"^F:C_9<=U'YC7(4%F/S<#_OG\S5OP;K.L6>F:BOBZ1XH[&?9'>W*>6)5
M)(SGOR.OO3/%OAH>(M`L)[*<1:U9PK+:L'`9^`2OZ9!]:Q=4\4MXG^$FIO<I
MY=_:-'#=)C'S!U^;'O\`SS324H))>3_S$VTVST-=<TM[JWM5OX#/=1B6",.-
MTB'/('<<&HT\2:))/Y":I:M+YP@V"0;O,_NX]>*\YL?^1^\%_P#8'3_T%ZL_
M#S1]/OO$7B*^NK5)KBTOR8';GRSN8Y'OP*ATHI-M_P!7&IMNQW;>)]"34_[-
M;5K07F[;Y)E&[=Z?7VK1G222WD2*3RY&0A7QG:<<&OG^QT^\UCPU<P6'A^XO
M+S^T#*=0C4':`.4SUSSFO?[?<+:+?G?L&[/7.*56FH6LQPDY'E#-XU7QNOA;
M_A+7\QH?-^T>0N/NYQC%>A/XBTG1A;Z?JVMVJWHC4/YCA2[8^\1VSUKD7_Y+
MU'_UY?\`LAKE+^WGU+Q#XPM8-#FU2ZFFV131J";;#'GGID#''I6S@IVOIHF1
M=Q/9=2UO2](MTN-1OX+:*0X1I'`W?3UKF_'OB*2W\"OJV@ZBN3*@2>$AA@G!
M'>N3&GM)XM\%:9J]L7V:=MEMYQD`C?P1^`_*IO%?A7_A$_AMJ5JEZ;F.>^25
M1LVB/)`P.3Z5$:<5*-WK_P`$;DVF>@:+K^G:@D%DFHP3WZVZ/-$K@L#M&20/
MK2-XO\.(H9M:L@#)Y7^N'WO2N#T2SM;#XJZ1':6\<"/I"NRQK@%BAR3[UR4M
ME:MX%UR]:WC-RFKJBS%?F53G@'TIJA%O?M^(>T:1[EJ>O:3HJQMJ6HV]J)/N
M>8X!;Z"N7^(OB*YL?"]EJ.AZB$$]TJB:$JP=2#WY]*Y^\M;?4OB;96]]"EQ"
MNB@A)!N`/EL<X^M<XQ)^$5J"20NLD`>@VTZ=))IBE-ZH]HU'Q#H^C>4NIZE;
MVKRC*K*X!/OBK$VJ6%OIW]HRWD"6>T-YY<;"#T.:\SU:SMM1^)FMQWL"7"0Z
M,6C609"$1K@CWY/YUCNQ?X2:$LS9A&K;7#'Y=N6X/MUJ5032U[?B5[1ZGJ\?
MB31M1ML6&L6KO,KB)DD!.57)./8<U3\-:@EIX8:\U3Q';:FB2-NO@0J`?W?P
MKD_#-GIQ\7>+YK*WMC##%B!XE!5,J<[2.F?:N3E8CX0Z<G)5M6;<@_B^4\4U
M13]U>0N=[GMNF:YI6LPO+INH0721\.8W!V_7TJ*R\3:'J5ZUE9:K:W%RN?W<
M<@)..N/7\*\_T+0=2N_$NNRPZ%<:'9:AIK0Q(ZA55\*.WOD_G4?@&PT0:I:Z
M5JVGM8>(M(9C&0VW[0,DYX^]@'\NE2Z44F[CYWH>L5PWQ-UO4]%M]);3;M[8
MSW>R0J`=RXZ<BNYKSCXP_P#'KH?_`%^_T%9T4G45RI_"=K=^(=&L+B2VO-3M
MH)HH_,=))`"J^N*>-<THZ4-5&H6_V$C/V@N-GIU^M>=ZY96M]\5]0CN[>.=%
MTEG59%R`P3@_6N98E_A=HD+$F-]78,O8CFM8T$TM>Q#J-7/:],UK3-:A:73+
MZ"[1#AC$X.T^_I5ZN8T3P9!H7BF_U>SG6."\C""SCB"K'C'/7V/;O73USR44
M_=-5>VI'YJ^M'FKZUB?V@/6E74$')^;V[57(%S;#ANG-*74=2,UBG4V<A0<9
MX"K5L316:![EQYA&0@ZBI<;#-`4M4;6[:ZW3-A(4J6WNTGCDF!Q&AP"?;O2:
M8$CV\,C;GB1CZE:D`"C`&`.PJ);A6M/M`^[MW4V2[1+5;D<QG!./0U*@D[I#
MNR>D#J>`>?2JMS=&&);F(AXCU_QJ/[1%?(6MW`E`Y0]356$72X7KQ2>:OK6/
M_:;QDHQZ<%6I&U%#R/E/IU%5R,5S9\U?6G@Y&:P?[0'K6W`V^WC;U4&E*-AF
M7XKT5_$/AJ\TN.4123H-CMT#`@C/MQ7"Z;X,\5WVHZ#%K$5G:V6AD;'BDW-*
M`0>GX#TKU*BJC5E%61+BF[G(^&?#NHZ7XP\0:G=+&+;4)`T!5\DC)ZCMUKCK
MGX?>+AIFIZ1!'8O:7%Z+E96EP\G7'TX.3FO7Z*I5I)W]/P$X)JQY]KOA7Q!#
MX@TKQ)H4=M/=VMLL$MO.^!D*1D'OP3^54;/P!KK^&/$0O6MTU+6'6184?Y%*
MONP3TYR:]/HH5:25@Y$>;:+X2\3IXGT'4]3BLDATZU^SLL,A+*H#`9SU)SVX
MK:\$^'-1T.^UV6_2-4OKOS8=C[LKENOIU%=?12E5E)6!02/)?^%?^+(;:;P_
M;26J:9+??:?MHE*R`8QC:/;MZ]Z]7B011)&"2$4#)ZG%/HI3J.>XXQ4=CC6\
M,ZD?BHGB()']@%MY9;?\V=I'3ZUAZSX+\40ZOKG]C"UEM-<(+RR2E'A^;)Q^
M.?7BO3J*:JR3$X)GGFI^#-=L+GP_J>C/!?7>DVWD2)<.5$G7YL_\"/Z52/P^
MUP?#^]TQGAEU*^NUN&3S/D0`]-QKU"BFJTD'(CB+3PMJD/C[3M9=(OLEOIRV
M\A$GS;PI'`],U@-\/M?/@_5=,\JW^TW6I"XC'G<%!ZGL:]6HH5:2#D1Y[KGA
M7Q#!X@LM>T..UN)DL1:RPSOM"G:5R#WZ_I5"X^'>LI\/[/183!+>B^^U3#?A
M5!!&`>_:O4:*%6DK>0<B//?$?A;Q&GBFYUK0HK6Y%]9&UECG?:8\J%)'KT%9
M>OZ/=^&?AWI6@&>UGNI[L>9;,"?M!+9V*>W)&3Q]:]6K'\0^%]+\3VT<.I1.
MWDMNBDC<JZ'O@TXUG=*6R$X;V.0\/ZC)I%^_A&Z\,VVCW%_`[PM;3;UD.T_>
M/)['OVJLOP[UF3X<PZ.Y@CU&VO3<HN_*..F,]NM=?H?@C1M`OFO[=;BXNRNT
M3W4QD=1Z#/2NAIRJV=X@H76IP&C^&O%4^J:OK6I746G7EY:^3;QP2&18FP,-
M@Y'\(_,U5T[PIXMU'Q/I.H^(3:1C2@?](B?=)<\DC./_`*W&:])HJ?;2'R(Y
M;PCJ^LZGJFN6^IF%HK&Z\F%HEP.Y()[D#;FJ_P`0_#6I>)(-,33DC8VUSYDG
MF/M^7':NKM[6WM%=;>".$.Y=@B@;F/4GW-35//:?-%#Y;JS.*O/"^J3>/[S6
M42+[)-IS6Z$O\V\KCIZ5B#X>ZVWP^M-,S`FI65ZURB%\HX],UZA15*M)6$X)
MG`Z'X>\4PZEKGB*]%K!J=Y;&.UMHY-T:O@8)]LJ/UJ'_`(NS_P!0G]*]$HI>
MU=]4@Y/,\R_M3_:_6C^U/]K]:XS^U3_>H_M4_P!ZN_V1C[1'=PZZ+9=T0!F/
M_+1OX/H/7WI+>]FO[Q(4<M)(>68]/4GV%<+_`&J?[U2QZZ\,,B1MM,HVLV>=
MOI^/>DZ78?M$>@:GXAAV+8V3_P"C1<%_^>A]?I5N[U06'AJTA#8ENP7/LN?_
M`-5>8)J1=U0-RQ`%7M;\0K>ZDQB?]Q"HAA_W5&`?QZ_C4>QU2'[1'I5MJ8/@
MN:?=RF8_S/\`]>J^@:JM_:76F,WSF-FB]_4?GS7$VVO!?!5]`7^;[9'@>Q!/
M_LM9=AXAET^^ANXF^>%PP'KZC\14JA=,/:+0[W2_$:6[-;7?S6LO#CNGO4%]
M=2:=>M%YF<8:.13]Y3T(-<;JFIQ+J<YMWS#(WF1_[K<@?KBHFUYY+5()&W"(
MGRVSRH/4?3O5JEU%[1';RZ\MW'^_XF4<2K_%[,/ZU5_M3_:_6N,_M4_WJ/[5
M/]ZJ5*P>T1V?]J?[7ZUZ'IK;],MG_O1*?TKPDZJ<?>KW#06WZ!I[_P!ZVC/_
M`(Z*Y\1#E2+A*Y?)`!).`.I-48=:L;AF6"1I=EP+=BBD@.5W=?3!ZT[6;.34
M-%O;*%@LEQ`\:D]`2"!FN=T[PU?P10[X+:WVZHEV8HGRJH(MA`X'.:YXI-:L
MMMW.K$\+,ZB5"8_O@,/E^OI3?MEKY?F?:8MG][>,>O6N$N?#>J6L&OWEQ!&W
MVJTD14M.2[&0LIVA<]#SG)ZTFFZ!+JVB11K8+"T=W<23":,(DC/"R@HN/NAF
M`YZ8-7[.-KW%S/L=\9X1(D9E0.XRJEAEA[#O4<M]:P0SS27$82W!:4[@=@`S
MS7*GPMJ']KZ;<&.V98([4/,7.^(Q!MRJ,<AMP[CIS3K#PM>0SZW&\-I':WT4
MBQ@GS&+LS'.=H(7G."3@].*GECW'=]CI8-2M;DP>1)YBW$1EC=1\I7COVZU8
MBFBG3?#(DBYQN1@1^E<NGAV_DL[.(QP6K1:3-9L$?(61MH##`''RD_C6CX9T
MV?3;&2.>PM+)F9?DMF+!L(J[CP!DX[#ICO2<4EHP39K+/"QD"S(3%]\!A\OU
M]*@?4[1)K6+S@QO&982GS!B`2>1[`UR8\):D%UV"..UAAOXF$67W,SERWWMH
M(4@\@YP3QQ5S3/#M];RV,TD5O`L5]<7+01MD1+(A"J.!GD^U/ECW%=]CHKG4
M;.TM);N>YC2&%-[ONR`OK1'?6\LJQH^X-%YP<#Y2N<=>E<CI_A'4DT?4K*[C
MM0T^GI:PX<L"RF0ACQQ]X>M7+WP[?7L$H2."U,FD&S$8?(23=G'`^[[T^6.U
MPN^QTOVNV\D3?:(O+;H^\;3^-.,\(D6,RH'<95=PRP]AWKC?^$1O)].CAEM;
M2(&\N+@VX;<D8>%D4#C!^8@]*G/AK4$UG1[R**V)M8(8KB1WW<(#G"D=>>&!
M'?-+ECW"[['1:CJUII9MQ=.0US*(8E49+,?;^M6?M$)=T\Z/=&,NNX94>_I6
M;K.DG4KS2IA'$XL[KS7\P<A=C#C\2/RK`_X134?[0U:41VRK<P7:1RA_FE,Q
M!4-QP%QCO[4*,6MQML[$31&(RB1#&`27##`QUYJE'K^ERQV<D=VC1WP8P/\`
MPM@9.3VX]:DL=/BM=&AL/)B55A$;(JC:3CGCW.:Y63PA>S^'-.TV2VM%>S@N
M(F&[*LS1E5<<=<\^U$5%[L&V=F9XA*(3*@D89";ADCUQ1)/##CS943/3<P&:
MY/\`X1:^_P"$LM=298WBC6$E_.(*%$92-N,G)/J!UR*M>+?#EQKKQM"D#>7:
MSQKYIZ.Q3:1Q_LGFCEC=*X7=MCHO/B$ODF5/,QNV;AG'KCTH$\+8Q*ASC&&'
M.>E<POAJ['C=M7=(WMV<.'\W!4>5L*[<<\\]<8[9JCH'@B_TSQ#%>W%S'):Q
M,Y6,$\!04AQ]$9LT<L;;A=]CM9)X82!+*B$]-S`9J-KZ!9(4#;_/+!&0;EX&
M3DCITK`\5^&Y]=N$>)('"6LD0\WL[/&01QZ*W--LO#=U:W5BRK"D5M?74Y5#
M@!)`P4`8]QQ1RQM>X7=]C9L]<L+]H%MY2QN(#<1Y4C*`@$\].2*M"[MC")A<
M1&,]'WC:?QKE(?"FHKID=JTD*.-'FLBP8\2.P(/3IQ45KX0NQI,%K-;P+B^-
MP\3R^8-OE%/[H&<X.`,?C3<8]Q7?8[$W$"LJF:,%\;06&6STQ38KR&7?AMNR
M1HSO&W)'7&>M<B_A"^<Z<[+;L]I:VD6XMRK1RAGP<>E37WAO4WAD,"P.YU&>
MX"O(5&R2-D'.#R-W2CECW"[['4O=6T>-]Q$N1D;G`R/6I00RAE(((R".]<5=
M^#;JZ-J9(K63R;:SB._G!C9B^..A!'UKHM(T^XL=%L;.8KYEO;QQOM.1E5`.
M/RJ7%):,:;['SK1117M'`%%%%`!FBBB@!PD<1F,,=C$$CU(Z?S--HHH`,GUH
MHHH`****``]*^B_#7_(LZ9_UZ1_^@BBBN+&?"C>ANS3HHHKSSJ"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
&HHHH`__9
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
